Shots:
- The CHMP has granted a positive opinion to Vevizye in moderate to severe dry eye disease adults treated with tear substitutes based on (ESSENCE-1 & ESSENCE-2) trials involving >1500 patients
- Vevizye showed improved ocular surface health, with a reduction in corneal fluorescein staining at D15 (~71.6% responded within 4wks.); additional benefits were observed at up to 56wks., verifying its efficacy & tolerability
- Vevizye (CyclASol) is a clear, 0.1% ciclosporin solution without oils, surfactants, or preservatives offering superior spreading and longer retention on the eye
Ref: Novaliq | Image: Novaliq| Press Release
Related News:- Astellas Reports the CHMP’s Positive Opinion of Zolbetuximab to Treat Gastric and Gastroesophageal Junction Cancer
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
